V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320003501 | 320002115 | 1.71 | null | Adjuvant (A) | 2014-06-17 | 2014-06-28 | BENDAMUSTINE + RITUXIMAB | Y | Y | 320022893 | CARBO + FLUOROURACIL |
| 320003502 | 320002116 | 1.7 | 78.4 | Neo-adjuvant (N) | 2017-11-02 | 2017-11-02 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320022894 | DOXORUBICIN EMBOLISATION |
| 320003503 | 320002117 | null | 50 | null | 2013-07-02 | 2013-07-08 | PEMBROLIZUMAB | N | N | 320022895 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003504 | 320002118 | 1.6 | 78.8 | null | null | 2016-01-04 | Docetaxel+Gemcitabine (no prior RT) | null | null | 320022897 | CISPLATIN + GEMCITABINE |
| 320003505 | 320002119 | 1.73 | 80.4 | Palliative (P) | null | 2016-08-30 | CARBOPLATIN + RT | N | Y | 320022903 | CARBO + FLUOROURACIL |
| 320003506 | 320002119 | null | 85.4 | Palliative (P) | 2014-06-26 | 2014-07-04 | IVA | 02 | N | 320022903 | LANREOTIDE |
| 320003507 | 320002120 | 1.61 | 63.4 | null | null | 2016-10-20 | Carboplatin + Etoposide iv&po | N | null | 320022906 | PACLITAXEL |
| 320003508 | 320002121 | 1.91 | 69.4 | Palliative (P) | 2013-11-25 | 2013-12-02 | IVA | 02 | N | 320022915 | CETUXIMAB + RT |
| 320003510 | 320002123 | 1.7 | 76.4 | null | 2013-05-01 | 2013-05-19 | Vinflunine | N | N | 320022929 | CETUXIMAB |
| 320003511 | 320002123 | 1.67 | 53 | Curative (C) | 2014-08-19 | 2014-09-09 | Fluorouricil + Folonic Acid (MdG) | 02 | Y | 320022929 | CARBOPLATIN + LIPOSOMAL DOX |
| 320003512 | 320002123 | 1.47 | 69.199 | Curative (C) | 2016-10-18 | 2016-10-22 | Paclitaxel (2 or 3 weekly) | N | Y | 320022929 | CAPECITABINE + CISPLATIN |
| 320003513 | 320002124 | 1.8 | null | Palliative (P) | 2015-08-14 | 2015-09-12 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 320022952 | CETUXIMAB |
| 320003514 | 320002125 | null | null | Not known (9) | 2014-04-10 | 2014-04-18 | Carboplatin + Etoposide iv&po | N | N | 320022958 | CETUXIMAB + CISPLATIN + FU |
| 320003515 | 320002126 | 1.85 | null | Neo-adjuvant (N) | 2015-05-11 | 2015-05-23 | Cetuximab + Radiotherapy Load | N | N | 320022959 | CAPECITABINE + CARBOPLATIN |
| 320003516 | 320002127 | null | null | Palliative (P) | 2014-03-28 | 2014-06-04 | Bevacizumab+Carbo+Pacliaxel | N | N | 320022967 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 320003517 | 320002128 | null | 52.4 | Palliative (P) | 2015-10-24 | 2015-10-31 | Vemurafenib | N | N | 320022973 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003518 | 320002128 | 1.6 | 70.1 | Palliative (P) | 2017-01-05 | 2017-01-15 | Bevacizumab 7.5mg/kg | 01 | N | 320022973 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003519 | 320002128 | 0 | 47.5 | Palliative (P) | 2017-03-02 | 2017-03-16 | CARBOPLATIN + RT | N | N | 320022973 | IVA |
| 320003520 | 320006952 | 1.6 | 17.5 | Palliative (P) | 2017-09-01 | 2017-09-12 | Carboplatin + Etoposide iv&po | null | N | 320022984 | IPILIMUMAB |
| 320003521 | 320006952 | 1.7 | 68 | Disease modification (D) | 2016-10-20 | 2016-10-24 | FLUOROURACIL | 01 | N | 320022984 | POUT TRIAL |
| 320003522 | 320002129 | 1.69 | null | Palliative (P) | 2016-02-07 | 2016-02-07 | NIVOLUMAB | 1 | null | 320022988 | CISPLATIN + FLUOROURACIL + RT |
| 320003523 | 320002130 | 1.56 | 54.4 | Neo-adjuvant (N) | 2014-12-30 | 2015-01-06 | Cisplatin + Vinorelbine (IV) | Y | N | 320022990 | MITOMYCIN INTRAVESICULAR |
| 320003524 | 320002130 | null | 54 | Palliative (P) | 2017-04-30 | 2017-06-03 | Cetuximab 7 day (>Cycle 2) | N | N | 320022990 | CISPLATIN + ETOPOSIDE |
| 320003525 | 320002131 | 1.61 | null | null | 2014-06-17 | 2014-06-24 | Bevacizumab+Carbo+Pacliaxel | 2 | N | 320023007 | CETUXIMAB |
| 320003526 | 320002132 | 1.63 | 0 | Curative (C) | 2013-08-06 | 2013-09-12 | PEMBROLIZUMAB | N | Y | 320023009 | CARBO + FLUOROURACIL |
| 320003527 | 320002133 | null | 0 | Palliative (P) | 2016-02-04 | 2016-02-06 | CISPLATIN + GEMCITABINE | 01 | N | 320023015 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003528 | 320002134 | 1.57 | 42.2 | null | 2015-02-09 | 2015-02-26 | GEMCITABINE | 2 | null | 320023020 | CISPLATIN + ETOPOSIDE |
| 320003529 | 320002135 | 1.81 | 59 | Palliative (P) | 2015-05-11 | 2015-05-23 | VAC | N | N | 320023024 | CAPECITABINE + CISPLATIN + RT |
| 320003530 | 320002136 | null | null | Curative (C) | 2017-05-03 | 2017-06-03 | Capecitabine + Oxaliplatin 21day | null | null | 320023025 | CISPLATIN + FLUOROURACIL + RT |
| 320003531 | 320002136 | 1.68 | null | Neo-adjuvant (N) | 2014-03-11 | 2014-03-31 | Bevacizumab 7.5mg/kg | N | N | 320023025 | ICON TRIAL |
| 320003532 | 320002137 | 1.6 | 62.4 | Curative (C) | 2016-07-13 | 2016-07-30 | ICON8 TRIAL | N | N | 320023036 | OXALIPLATIN + MDG |
| 320003533 | 320002138 | 1.58 | 64 | Disease modification (D) | 2015-12-21 | 2016-01-09 | Hydroxycarbamide | N | N | 320023038 | ICON TRIAL |
| 320003534 | 320002139 | 1.71 | 72.5 | Palliative (P) | 2017-06-28 | 2017-06-28 | Dacarbazine | N | N | 320023042 | DOCETAXEL |
| 320003535 | 320002140 | 1.78 | 77 | Palliative (P) | 2016-07-30 | 2016-08-29 | PEMBROLIZUMAB | N | N | 320023043 | CETUXIMAB + RT |
| 320003536 | 320002140 | 1.8 | 99.5 | Neo-adjuvant (N) | 2016-02-07 | 2016-02-08 | Carboplatin + Vinorelbine Oral | N | N | 320023043 | CISPLATIN + PEMETREXED |
| 320003537 | 320002140 | 1.75 | 77 | Curative (C) | 2014-11-01 | 2014-11-05 | ECX | 02 | N | 320023043 | TEMOZOLOMIDE + RT |
| 320003538 | 320002141 | -1 | 69.3 | null | 2016-02-23 | 2016-02-29 | Trial Unspecified | N | null | 320023056 | NOT MATCHED |
| 320003539 | 320002142 | null | 63.65 | Neo-adjuvant (N) | 2017-08-18 | 2017-08-22 | Trial Unspecified | 02 | N | 320023057 | CARBOPLATIN + ETOPOSIDE |
| 320003540 | 320002142 | 1.66 | 68.6 | Palliative (P) | 2014-01-10 | 2014-01-15 | EC | 02 | N | 320023057 | CISPLATIN + GEMCITABINE |
| 320003541 | 320002143 | 0 | null | Curative (C) | 2016-08-19 | 2016-09-11 | Cisplatin + Gemcitabine (D 1 & 8) | N | Y | 320023065 | MITOMYCIN INTRAVESICULAR |
| 320003542 | 320002144 | null | 62 | Palliative (P) | null | 2013-11-25 | CARBOPLATIN + Cetuximab + FLUOROURACIL | null | null | 320023066 | TEMOZOLOMIDE |
| 320003543 | 320002144 | null | null | null | null | 2012-09-07 | Imatinib 400mg | N | null | 320023066 | CARBO + FLUOROURACIL |
| 320003544 | 320002145 | null | null | Neo-adjuvant (N) | 2013-02-17 | 2013-02-19 | Ipilimumab | null | null | 320023076 | CETUXIMAB + RT |
| 320003545 | 320002146 | null | null | Curative (C) | 2014-06-15 | 2014-07-08 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320023084 | ECX |
| 320003546 | 320002147 | 1.56 | 63.5 | Neo-adjuvant (N) | 2017-07-29 | 2017-08-12 | Carboplatin + Cetux + FU (Cycle 1) | Y | N | 320023087 | DOXORUBICIN |
| 320003547 | 320002148 | 1.64 | null | Disease modification (D) | 2016-01-25 | 2016-01-25 | Cisplatin + Vinorelbine (IV) | 02 | N | 320023095 | EVEROLIMUS |
| 320003548 | 320002149 | 1.71 | 58.2 | Neo-adjuvant (N) | 2013-09-09 | 2013-09-12 | Cetuximab + Radiotherapy Load | 01 | N | 320023097 | CARBOPLATIN + LIPOSOMAL DOX |
| 320003549 | 320002149 | 1.71 | 66 | Adjuvant (A) | null | 2014-10-15 | CETUXIMAB | N | N | 320023097 | CETUXIMAB + RT |
| 320003550 | 320002149 | null | 79.9 | Palliative (P) | 2013-08-10 | 2013-08-11 | ECX | Y | null | 320023097 | BLEOMYCIN |
| 320003551 | 320002150 | 1.78 | 101 | Curative (C) | 2016-01-22 | 2016-02-12 | Carboplatin + Etoposide IV 3 day | 2 | Y | 320023104 | CISPLATIN + DOCETAXEL + FLUOROURACIL |